Stella Cooremans Pena
Family · Boerne, TXNPI 1790157758
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 444 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 444 payments — averaging $22.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Johnson & Johnson$1K
- UCB, Inc.$845
- Lilly USA, LLC$785
- Mallinckrodt Hospital Products Inc.$767
- Novartis$756
- plus $3K from 21 others
What the payments were for
- Food & beverage$9,90699%
- Education$1141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 109 | $2,110 |
| Johnson & Johnson | 59 | $1,361 |
| UCB, Inc. | 25 | $845 |
| Lilly USA, LLC | 29 | $785 |
| Mallinckrodt Hospital Products Inc. | 33 | $767 |
| Novartis | 34 | $756 |
| GSK | 23 | $611 |
| AstraZeneca(2 entities) | 27 | $519 |
| Genentech USA, Inc. | 27 | $459 |
| AbbVie | 5 | $424 |
| Pfizer | 23 | $381 |
| Boston Scientific | 10 | $172 |
| Pacira Therapeutics, Inc. | 6 | $160 |
| Fresenius Kabi USA, LLC | 5 | $139 |
| E.r. Squibb & Sons, L.L.C. | 5 | $98 |
| Ferring Pharmaceuticals Inc. | 6 | $95 |
| Organon | 4 | $74 |
| Radius Health, Inc. | 3 | $70 |
| Celltrion USA Inc. | 2 | $43 |
| Actelion Pharmaceuticals US, Inc. | 2 | $29 |
| Boehringer Ingelheim | 1 | $21 |
| Sanofi | 1 | $20 |
| Aurinia Pharma U.S., Inc. | 1 | $19 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $16 |
| ANI Pharmaceuticals, Inc. | 1 | $15 |
| Cumberland Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,020 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 22 | $196,722 |
| Enbrel SureclickEtanercept | 19 | $164,108 |
| Mycophenolate Mofetil | 20 | $5,967 |
| Hydroxychloroquine Sulfate | 125 | $5,731 |
| Leflunomide | 52 | $3,503 |
| Duloxetine Hcl | 62 | $2,001 |
| MethotrexateMethotrexate Sodium | 97 | $1,981 |
| Gabapentin | 48 | $1,863 |
| Sulfasalazine DrSulfasalazine | 37 | $1,748 |
| Cevimeline Hcl | 11 | $1,238 |
| Colchicine | 11 | $968 |
| Azathioprine | 19 | $683 |
| Pregabalin | 19 | $498 |
| Sulfasalazine | 23 | $475 |
| Celecoxib | 17 | $360 |
Paid to pharmacies, not to this prescriber.
Other family in Boerne
- David WeirDallas$959K
- Robin BeachHouston$428K
- April LopezMcAllen$417K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
- Jill CampbellShenandoah$182K
- Angela AchaPflugerville$174K
- Susan BowlinIrving$164K
- Stephanie RodriguezCorpus Christi$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.